You are here: Home NBIA News and Events

News and Current Events


Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN

For further information, please read the press release. The statement of the principle investigator Prof. Thomas Klopstock's (in German) can be found here.

July 22, 2019, NBIA Patient registry is progressing successfully
The total number of visit entries in the NBIA patient registry amounts now to 379 entered patients. Further entries are planned.
July 01, 2019 Results from Phase 3 TIRCON Study of Deferiprone in Patients with PKAN

...have been published in Lancet Neurology, the publication abstract is available here.

June 17, 2016, Orphan drug designation granted

The European Medicines Agency (EMA) has granted orphan drug designation to a new candidate compound CAB1803 for the treatment of PKAN, developed by TIRCON partners Acies Bio and University Medical Centre Groningen. For further information, please read the press release.

March 9, 2015, Clinical trial fully randomized

The Clinical trial of Deferiprone in PKAN is now fully randomized.

December 11, 2013, A TIRCON patent has recently been filed

TIRCON partners UMCG and Acies Bio developed a new candidate compound for the treatment of PKAN. For further information, please read the press release.


past events

April, 7-8, 2017, 6th International Symposium on NBIA

The 6th International Symposium on Neurodegeneration with Brain Iron Accumulation & Related Disorders took place on April 7th and 8th in Stevenson, Washington, USA. For more information, please visit http://bit.ly/NBIASymposium.